UCB  14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
Confidential  Page 1 of 49 PROTOCOL DV0004  AMENDMENT 1  
(NORTH AMERICA AND E U SUBSTUDY TO PA0012 ) 
A MULTICENTER, RANDO MIZED, OPEN -LABEL ST UDY TO 
EVALUATE THE SAFE AN D EFFECTIVE USE OF TH E 
PREFILLED SAFETY SYR INGE OR AUTO -INJECTO R FOR 
THE SUBCUTANEOUS SEL F-INJECTION OF BIMEK IZUMAB 
SOLUTION BY SUBJECTS  WITH ACTIVE PSORIAT IC 
ARTHRITIS  
PHASE 3  
IND Number: 128708  
EudraCT number: 2018 -004725 -86 
Sponsor:  
UCB Biopharma SRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Protocol/Amendment number  Date  Type of amendment  
Final protocol  05 Feb 2019  Not applicable  
Protocol Amendment 1  14 May 2020  Nonsubstantial  
Confidential Material  
Confidential  
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 2 of 49 STUDY CONTACT INFORMATION  
Sponsor  
UCB Biopharma SRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Sponsor Study Physician  
Name:   
Address:  UCB Celltech.  
208 Bath Road  
Slough SL1 3WE  
UNITED KINGDOM  
Phone:   
Clinical Project Manager  
Name:   
Address:  UCB BIOSCIENCES Inc.  
8010 Arco Corporate Drive  
Raleigh, NC 27617  
UNITED STATES  
Phone:   
Clinical Trial Biostatistician  
Name:   
Address:  UCB  
208 Bath Road  
Slough SL1 3WE  
UNITED KINGDOM  
Phone:   
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 3 of 49 Clinical Monitoring Contract Research Organization  
Name:  PAREXEL International (IRL) Limited -Ireland  
Address:  Ireland Limited at 70 Sir John Rogerson’s Quay, Dublin 2, 
Ireland  
Phone:  +353 (1) 477 3171  
Fax: +353 (1) 477 3308  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 4 of 49 SERIOUS ADVERSE EVENT AND PRODUCT QUALITY COMPLAINTS 
REPORTING  
Serious adverse event reporting (24h)  
Email:  DS_ICT@ucb.com  
Fax: +1 800 880 6949 or +1 866 890 3175  
Product Quality Complaints Reporting (24h)  
Email:  qactscomplaints@ucb.com  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 5 of 49 TABLE OF CONTENTS  
TABLE OF CONTENTS  ................................ ................................ ................................ ...........  5 
LIST OF ABBREVIATION S ................................ ................................ ................................ .... 9 
1 SUMMARY  ................................ ................................ ................................ .....................  11 
2 INTRODUCTION  ................................ ................................ ................................ ...........  13 
3 STUDY OBJECTIVES  ................................ ................................ ................................ .... 13 
3.1 Primary objective  ................................ ................................ ................................ .........  13 
3.2 Secondary objective  ................................ ................................ ................................ ..... 14 
3.3 Other objectives  ................................ ................................ ................................ ...........  14 
4 STUDY VARIABLES  ................................ ................................ ................................ ..... 14 
4.1 Outcome variables  ................................ ................................ ................................ ....... 14 
4.1.1  Primary outcome variable  ................................ ................................ ....................  14 
4.1.2  Secondary outcome variable  ................................ ................................ ................  14 
4.1.3  Other variables  ................................ ................................ ................................ ..... 15 
4.1.3.1  Outc ome variables  ................................ ................................ .....................  15 
4.1.3.2  Pharmacokinetic variable  ................................ ................................ ..........  15 
4.1.3.3  Immunological variable  ................................ ................................ .............  15 
4.1.3.4  Safety variable  ................................ ................................ ...........................  15 
5 STUDY DESIGN  ................................ ................................ ................................ .............  15 
5.1 Study description  ................................ ................................ ................................ .........  15 
5.1.1  Study duration per subject  ................................ ................................ ...................  16 
5.1.2  Planned number of subjects and sites  ................................ ................................ .. 17 
5.1.3  Anticipated regions and countries  ................................ ................................ ....... 17 
5.2 Schedule of study assessments ................................ ................................ .....................  17 
5.3 Schematic diagram  ................................ ................................ ................................ ....... 23 
5.4 Rationale for study design and selection of dose  ................................ .........................  23 
6 SELECTION AND WITHDR AWAL OF SUBJECTS  ................................ ...................  23 
6.1 Inclusion criteria  ................................ ................................ ................................ ..........  23 
6.2 Exclusion criteria  ................................ ................................ ................................ .........  24 
6.3 Withdrawal criteria  ................................ ................................ ................................ ...... 24 
7 INVESTIG ATIONAL MEDICINAL PR ODUCT AND INVESTIGAT IONAL DEVICE 24 
7.1 Description of device presentations  ................................ ................................ .............  24 
7.1.1  Bimekizumab -SS-1mL  ................................ ................................ ........................  24 
7.1.1.1  Instruction for use of bimekizumab -SS-1mL  ................................ ............  25 
7.1.2  Bimekizumab -AI-1mL  ................................ ................................ ........................  25 
7.1.2.1  Instruction for use of bimekizumab -AI-1mL  ................................ ............  26 
7.2 Treatment to be administered ................................ ................................ .......................  26 
7.3 Packaging  ................................ ................................ ................................ .....................  27 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 6 of 49 7.4 Labeling  ................................ ................................ ................................ .......................  27 
7.5 Handling and storage requirements  ................................ ................................ .............  27 
7.6 Drug and device presentation accountability  ................................ ...............................  27 
7.7 Procedures for monitoring subject compliance  ................................ ............................  28 
7.8 Concomitant medications/treatments  ................................ ................................ ...........  28 
7.8.1  Permitted concomitant treatments (medications and therapies)  ..........................  28 
7.8.2  Prohibited concomitant treatments (medications and therapies)  .........................  28 
7.9 Blinding ................................ ................................ ................................ ........................  28 
7.10  Randomization and numbering of subjects  ................................ ................................ .. 28 
8 STUDY PROCEDURES BY VISIT  ................................ ................................ ...............  28 
8.1 Treatment Period  ................................ ................................ ................................ ..........  29 
8.1.1  Unscheduled Visit  ................................ ................................ ................................  29 
9 ASSESSMENT OF SELF -INJECTION  ................................ ................................ ..........  29 
9.1 Assessment of injection site pain  ................................ ................................ .................  29 
9.2 Assessment of self -injection experience by SIAQ  ................................ .......................  29 
9.3 Evaluation of post -use structural, mechanical, and functional integrity of 
self-injecting device presentations  ................................ ................................ ...............  30 
10 ASSESSMENT OF PHARMA COKINETIC AND IMMUNO LOGICAL VARIABLES 30 
11 ASSESSMENT OF SAFETY  ................................ ................................ ..........................  31 
11.1  Adver se events (device presentations)  ................................ ................................ .........  31 
11.1.1  Definitions (device presentations)  ................................ ................................ ....... 31 
11.1.1.1  Adverse device effect (device presentations)  ................................ ............  31 
11.1.1.2  Serious adverse device effects  ................................ ................................ ... 31 
11.1.1.3  Device deficiency (device presentations)  ................................ ..................  32 
11.1.2  Procedures for reporting and recording adverse device effects and device 
deficiencies  ................................ ................................ ................................ ..........  32 
11.1.2.1  Reporting of adverse device effects  ................................ ..........................  33 
11.1.2.2  Reporting of device deficiencies  ................................ ...............................  33 
11.1.2.3  Reporting of serious adverse device effects including device defici encies 
with risk of serious adverse event  ................................ .............................  33 
11.1.2.4  Rule for repetition of an adverse device effect, serious adverse device 
effect, and/or device deficiency  ................................ ................................ . 34 
11.1.3  Follow up of adverse device effects and serious adverse device effects  .............  34 
11.2  Pregnancy  ................................ ................................ ................................ .....................  35 
11.3  Suspected transmission of an infectious agent ................................ .............................  35 
11.4  Overdose of investigational medicinal product  ................................ ...........................  35 
11.5  Safety signal detection  ................................ ................................ ................................ . 35 
11.6  Other safety measurements  ................................ ................................ ..........................  35 
11.6.1  Vital signs measurement  ................................ ................................ ......................  35 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 7 of 49 12 EFFICACY ASSESSMENTS  FOR PA0012  ................................ ................................ ... 36 
13 STUDY MANAGEMENT AND  ADMINISTRATION  ................................ .................  36 
13.1  Adherence to protocol  ................................ ................................ ................................ .. 36 
13.2  Monitoring  ................................ ................................ ................................ ...................  36 
13.2.1  Definition of source data  ................................ ................................ .....................  36 
13.2.2  Source data verification  ................................ ................................ .......................  37 
13.3  Data handling  ................................ ................................ ................................ ...............  37 
13.3.1  Case Report form completion  ................................ ................................ ..............  37 
13.3.2  Database entry and reconciliation  ................................ ................................ ........  37 
13.3.3  Subject Screening and Enrollment log/Subject Identification Code list ..............  38 
13.4  Termination of the study  ................................ ................................ ..............................  38 
13.5  Archiving and data retention  ................................ ................................ ........................  38 
13.6  Audit and inspection  ................................ ................................ ................................ .... 39 
13.7  Good Clinical Practice  ................................ ................................ ................................ . 39 
14 STATISTICS  ................................ ................................ ................................ ...................  39 
14.1  Definition of a nalysis sets  ................................ ................................ ............................  39 
14.2  General statistical considerations  ................................ ................................ .................  40 
14.3  Planned analyses of outcome variables  ................................ ................................ ........  40 
14.3.1  Analysis of the primary outcome variable  ................................ ...........................  40 
14.3.2  Analysis of the secondary outcome variable  ................................ .......................  40 
14.3.3  Analysis of other outcome variables  ................................ ................................ .... 40 
14.4  Planned pharmacokinetic analyses  ................................ ................................ ..............  40 
14.5  Planned safety analyses ................................ ................................ ................................  41 
14.6  Planned efficacy analyses  ................................ ................................ ............................  41 
14.7  Handling of protocol deviations ................................ ................................ ...................  41 
14.8  Handling of dropouts or missing data  ................................ ................................ ..........  41 
14.9  Planned interim analysis and data monitoring  ................................ .............................  42 
14.10  Determination of sample size  ................................ ................................ .......................  42 
15 ETHICS AND REGULATOR Y REQUIREMENTS  ................................ ......................  42 
15.1  Informed consent  ................................ ................................ ................................ .........  42 
15.2  Subject identification cards  ................................ ................................ ..........................  43 
15.3  Institutional Review Boards and Independent Ethics Committees  ..............................  43 
15.4  Subject privacy ................................ ................................ ................................ .............  44 
15.5  Protocol amendments  ................................ ................................ ................................ ... 44 
16 FINANCE, INSURANCE, AND PUBLICATION  ................................ .........................  44 
17 REFERENCES  ................................ ................................ ................................ ................  44 
18 APPENDICES  ................................ ................................ ................................ .................  45 
18.1  Protocol Amendment 1  ................................ ................................ ................................  45 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 8 of 49 19 DECLARATION AND SIGN ATURE OF INVESTIGATO R ................................ ....... 48 
20 SPONSOR DECLARATION  ................................ ................................ ..........................  49 
 
LIST OF TABLES  
Table  5‒1:  Schedule of study assessments for DV0004  ................................ ....................  18 
Table  5‒2:  Schedule of study assessments for corresponding visits in PA0012  ...............  20 
 
LIST OF FIGURES  
Figure  5‒1:  Schematic diagram  ................................ ................................ ...........................  23 
Figure  7-1: Bimekizumab -SS-1mL  ................................ ................................ ....................  25 
Figure 7-2: Bimekizumab -AI-1mL  ................................ ................................ .....................  26 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 9 of 49 LIST OF ABBREVIATION S 
ADE  adverse device effect  
AE adverse event  
bimekizumab -AI-1mL  1mL bimekizumab auto -injector  
bimekizumab -SS-1mL  1mL bimekizumab safety syringe  
BMI  body mass index  
CDMS  clinical data management system  
CI confidence interval  
CRO  contract research organization  
ECG  electrocardiogram  
eCRF  electronic Case Report form  
FAS Full Analysis Set(s)  
FAS-a Full Analysis Set for the bimekizumab -AI-1mL  
FAS-s Full Analysis Set for the bimekizumab -SS-1mL  
GCP  Good Clinical Practice  
ICF Informed Consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
IFU instructions for use  
IL interleukin  
IMP investigational medicinal product  
IRB Institutional Review Board  
IRT interactive response technology  
PFS prefilled syringe  
PK pharmacokinetic(s)  
PKS Pharmacokinetic Set  
PKS-a Pharmacokinetic Set for the bimekizumab -AI-1mL  
PKS-s Pharmacokinetic Set for the bimekizumab -SS-1mL  
PS Patient Safety  
PsA psoriatic arthritis  
Q4W  every 4 weeks  
SADE  serious adverse device effect  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 10 of 49 SAE  serious adverse event  
SAP Statistical Analysis Plan  
sc subcutaneous  
SFU safety follow -up 
SIAQ  Self-injection Assessment Questionnaire  
SOP Standard Operating Procedure  
SS Safety Set(s)  
SS-a Safety Set for the bimekizumab -AI-1mL  
SS-s Safety Set for the bimekizumab -SS-1mL  
USADE  unanticipated serious adverse device effect  
VAS  visual analog scal e 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 11 of 49 1 SUMMARY  
DV0004 is a Phase 3, multicenter, open -label, randomized, noncomparator, North America and 
Europe substudy to PA0012 in adult subjects with active psoriatic arthritis (PsA) to evaluate the 
safe and effective use of 2 single -use disposable self -injecting device presentations for the 
subcutaneous (sc) administration of bimekizumab solution (the investigational medicinal product 
[IMP]). To provide patients with PsA with options for the self -administration of bimekizumab, 
DV0004 will evaluate 2  investigational self -injecting device presentations, which are drug 
product (IMP) associated with a functional secondary packaging: the 1mL bimekizumab safety 
syringe (bimekizumab -SS-1mL) and the 1mL bimekizumab auto -injector 
(bimekizumab -AI-1mL).  
DV0004 is a substudy of PA0012, which is a multicenter, open -label, long -term safety study for 
subjects with PsA who complete 1 of the Phase  3 feeder studies (PA0010 or PA0011). The 
PA0012 study will evaluate the long -term safety, tolerability, and efficacy of bimekiz umab in 
subjects with PsA, and study personnel qualified in sc injection technique will administer 
bimekizumab to subjects (except for specified study visits at which subjects may self -administer) 
in a 1mL True North prefilled syringe (referred to througho ut this protocol as the 1mL PFS). 
Subjects will begin the DV0004 substudy and the PA0012 study at the same time. The DV0004 
substudy will include all PA0012 study assessments from Baseline to Week  4 (inclusive). 
However, subjects in the DV0004 substudy wil l self -administer bimekizumab at Baseline and at 
Week 4.  
During the 4 -week Treatment Period of DV0004, subjects will receive bimekizumab 160mg 
every 4 weeks (Q4W). This dose regimen will remain stable for the entire 4 -week Treatment 
Period of DV0004 (consi stent with PA0012). In the DV0004 substudy, subjects will be randomly 
assigned to 1 of the 2  self-injecting device presentations and will self -administer bimekizumab at 
Baseline and at Week  4. A safety follow -up (SFU) telephone call will occur 1  week after  the last 
self-administration in DV0004 (Week 5). After Week 5 in the DV0004 substudy, subjects will 
continue in PA0012 (the next visit after DV0004 completion will be the Week 8 Visit in 
PA0012). At Week  8 in PA0012, study personnel qualified in sc inject ion technique will 
administer bimekizumab to subjects in a 1mL PFS, or the subject/caregiver/appropriate designee 
will perform administration under the supervision of the site staff after training . 
To compensate for subjects who have different study treatm ents between the feeder studies and 
DV0004, DV0004 is planned to enroll approximately 200 subjects (100 subjects per device 
presentation arm) to ensure that approximately 50 subjects per device presentation arm are 
evaluable for steady state trough pharmac okinetic (PK) level analyses. Within each device 
presentation arm, subjects will be divided into tertiles by body mass index (BMI); there will be 
approximately 33  subjects per tertile, which is expected to yield approximately 16 to 17  subjects 
per tertile who are evaluable for steady state trough PK level analyses.  
The primary objective of the DV0004 substudy is to evaluate for each self -injecting device 
presentation the ability of subjects with PsA to safely and effectively self -inject bimekizumab 
4 weeks after training in self -injection technique using the bimekizumab -SS-1mL or the 
bimekizumab -AI-1mL. The primary outcome variable is the percentage of subjects able to 
self-administer safe and effective injections using the bimekizumab -SS-1mL or the 
bimekizu mab-AI-1mL at Week 4.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 12 of 49 Safe and effective self -injection will be evaluated by the study personnel and is defined as:  
• Complete dose delivery: Subject self -injects the complete dose of bimekizumab as confirmed 
by a visual inspection of the bimekizumab -SS-1mL or the bimekizumab -AI-1mL, which 
shows that the IMP is delivered completely (ie, container is empty), and 
• No adverse device effects (ADEs) that would preclude continued use of the device 
presentation for self -injection (ie, no serious adverse device effect s [SADEs] and/or ADEs 
leading to withdrawal from the DV0004 substudy)  
The secondary study objectives and other study objectives are provided in Section  3.2 and 
Section  3.3, respectively. Of note, one of the other study objectives is to ass ess trough PK levels 
associated with self -injection using the test device presentation, injection by study personnel 
using the 1mL PFS, injection site (abdomen or thigh), and BMI category (by tertile). The 
secondary outcome variable, other outcome variable s, and the other safety variable are listed in 
Section  4.1.2 , Section  4.1.3 , and Section  4.1.3.4 , respectively.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 13 of 49 2 INTRODUCTION  
Psoriatic arthritis is a common, chronic inflammatory disease cha racterized by a series of linked 
cellular changes in the skin. Bimekizumab (UCB4940; the IMP) is an engineered, humanized 
full length monoclonal antibody of immunoglobulin G1 subclass that selectively and potently 
inhibits the activity of interleukin (IL) -17A and IL -17F in vitro. Interleukin -17A and IL -17F are 
key proinflammatory cytokines believed to play important roles in autoimmune and 
inflammatory diseases. Bimekizumab is being developed for the treatment of patients with 
inflammatory diseases such as PsA, psoriasis, and axial spondyloarthritis.  
It is important for patients who may use bimekizumab for the treatment of active PsA to have 
options for the self -injection of bimekizumab that fit their needs and preferences. Whilst some 
patients may prefer to  manually regulate various tasks comprising the self -injection process (eg, 
needle visibility of skin penetration by needle, control speed of self -injection), others may prefer 
a more automated process (eg, do not wish to see the needle, desire an automati c injection). UCB 
therefore intends to provide patients with two different options to self -inject bimekizumab.  
The DV0004 study is a substudy of the PA0012 study. PA0012 will evaluate the long -term 
safety, tolerability, and efficacy of bimekizumab in subje cts with PsA; study personnel will 
administer bimekizumab in a 1mL PFS (except at specified study visits at which subjects may 
self-administer) . The DV0004 substudy will evaluate 2 self -injecting device presentations: the 
1mL bimekizumab -SS-1mL and the 1mL  bimekizumab -AI-1mL. Subjects will begin the 
DV0004 substudy and the PA0012 study at the same time. The DV0004 substudy will include all 
PA0012 study assessments from Baseline to Week  4 (inclusive). However, subjects in the 
DV0004 substudy will self -admini ster bimekizumab at Baseline and at Week 4.  
In the DV0004 substudy, the self -injecting device presentations are drug product (IMP) 
associated with a functional secondary packaging (either the bimekizumab -SS-1mL or 
bimekizumab -AI-1mL). The bimekizumab -SS-1mL and the bimekizumab -AI-1mL are each 
single integral units which are intended exclusively for use in the given combination and are not 
reusable. Therefore, compliance to the EU Medical Device Regulation (except for Annex 1) and 
European C onformity marking (CE marking) is not foreseen. Full descriptions of the 2  devices 
are provided in  Section  7.1.1  and Section  7.1.2 , respectively.  
The proposed study is planned to demonstrate that adult subjects with PsA can safely and 
effectively self -inject bimekizumab using the bimekizumab -SS-1mL or the 
bimekizumab -AI-1mL.  
3 STUDY OBJECTIVES  
3.1 Primary objective  
The primary objective of the study is to evaluate for each self -injecting device presentation the 
ability of subjects with PsA to safely and effectively self -inject bimekizumab 4  weeks after  
training in self -injection technique using the bimekizumab -SS-1mL or the 
bimekizumab -AI-1mL.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 14 of 49 3.2 Secondary objective  
The secondary objective of the study is to evaluate the ability of subjects with PsA to safely and 
effectively self -inject bimekizumab immedia tely after training in self -injection technique using 
the bimekizumab -SS-1mL or the bimekizumab -AI-1mL.  
3.3 Other objectives  
Other objectives of the study are to evaluate the following:  
• Subject experience of self -injection as assessed by the pain visual analog  scale (VAS) for 
injection site pain and the Self -injection Assessment Questionnaire (SIAQ)  
• Trough PK (trough bimekizumab) levels associated with self -injection using the test 
self-injecting device presentations, injection by study personnel using the 1mL PFS, injection 
site (abdomen or thigh), and BMI category (by tertile)  
• Immunogenicity of bimekizumab associated with self -injection using the self -injecting 
device presentations and injection by study personnel using the 1mL PFS  
• The structural and mechanica l integrity of the bimekizumab -SS-1mL and the 
bimekizumab -AI-1mL after completion of self -injection  
• The functional integrity of the bimekizumab -SS-1mL and the bimekizumab -AI-1mL after 
completion of self -injection  
• The overall safety and tolerability of self -injections using the self -injecting device 
presentations  
4 STUDY VARIABLES  
4.1 Outcome variables  
4.1.1  Primary outcome variable  
The primary outcome variable is the ability to self -administer safe and effective injections using 
the bimekizumab -SS-1mL or the bimekizumab -AI-1mL at Week 4. Safe and effective 
self-injection will be evaluated by the study personnel and is defined as:  
• Complete dose delivery: Subject self -injects the complete dose of bimekizumab as confirmed 
by a visual inspection of the bimekizumab -SS-1mL or the bimekizumab -AI-1mL which 
shows that the IMP is delivered completely (ie,  container is empty), and 
• No ADEs that would preclude continued use of the device presentations for self -injection 
(ie, no SADEs and/or ADEs leading to withdrawal from t he DV0004 substudy).  
4.1.2  Secondary outcome variable  
The secondary outcome variable is the ability to self -administer safe and effective injections 
using the bimekizumab -SS-1mL or the bimekizumab -AI-1mL at Baseline (the first self -injection 
visit, immediately a fter training in self -injection technique). Safe and effective self -injection will 
be evaluated by study personnel and is defined using the same criteria as the primary outcome 
variable (see Section  4.1.1 ). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 15 of 49 4.1.3  Other variables  
4.1.3.1  Outcome variables  
The other outcome variables are:  
• Responses to pre -injection SIAQ (versions 2.0 and 2.1) at Baseline  
Whenever SIAQ is assessed, version 2.0 of the SIAQ will be used  to assess 
bimekizumab -SS-1mL and version 2.1 of the SIAQ will be used to assess 
bimekizumab -AI-1mL (see Section  9.1). 
• Injection site pain (using a VAS; 100mm) by visit after self -injection using the assigned 
self-injecting device presentations at Baseline and Week  4 
• Responses to post -injection SIAQ (versions 2.0 and 2.1) by visit following self -injection 
using the assigned self -injecting device prese ntations at Baseline and Week 4  
• The structural and mechanical integrity of the bimekizumab -SS-1mL and the 
bimekizumab -AI-1mL after completion of self -injection using the assigned self -injecting 
device presentations  
• The functional integrity of the bimekizum ab-SS-1mL and the bimekizumab -AI-1mL after 
completion of self -injection using the assigned self -injecting device presentations  
4.1.3.2  Pharmacokinetic variable  
The PK variable is trough PK (bimekizumab) levels associated with self -injection using the test 
self-injecting device presentations, injection by study personnel using the 1mL PFS, injection 
site (abdomen or thigh), and BMI category (by tertile). Trough levels will be assessed at 
Baseline, Week 4, and Week 8 (in PA0012).  
4.1.3.3  Immunological variable  
The immunologi cal variable is the anti -bimekizumab antibody, which will be collected as 
described in the PA0012 protocol . 
4.1.3.4  Safety variable  
The other safety variable is the occurrence of ADEs. Additional safety and tolerability variables 
will be collected as described in the PA0012 protocol.  
5 STUDY DESIGN  
5.1 Study description  
DV0004 is a Phase 3, multicenter, open -label, randomized, noncomparator, North America and 
Europe substudy to PA0012. PA0012 will evaluate the long -term safety, tolerability, and 
efficacy of bimekizumab in adult subjects with PsA. In the DV0004 substudy, the safe and 
effective use of the bimekizumab -SS-1mL or the bimekizumab -AI-1mL for the  sc self-injection 
of bimekizumab solution by adult subjects with PsA will be evaluated.  
Subjects from sites in the PA 0012 feeder studies, PA0010 and PA0011, will be eligible for the 
DV0004 substudy. The DV0004 substudy will maintain all study assessments of the main 
PA0012 study from Baseline to Week 4 (inclusive). However, only subjects in the DV0004 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 16 of 49 substudy will self -administer bimekizumab using the bimekizumab -SS-1mL or the 
bimekizumab -AI-1mL at Baseline and Week 4. At DV0004 Baseline, each subject will be 
provided with training in self -injection and will receive the instructions for use (IFU) and any 
other applicable  training materials. S ubjects in the DV0004 substudy will perform self -injections 
at the DV0004 Baseline (corresponding to the Entry Visit of PA0012) with a subsequent 
self-injection at the DV0004 Week  4 Visit (corresponding to Week  4 of PA0012).  
During th e 4-week Treatment Period of DV0004, subjects will receive bimekizumab 160mg 
Q4W. This dose regimen will remain stable for the entire 4 -week Treatment Period of DV0004 
(consistent with PA0012). The DV0004 substudy will evaluate 2  self-injecting device 
presentations: the bimekizumab -SS-1mL and the bimekizumab -AI-1mL. Baseline for DV0004 
and the Entry Visit for PA0012 will occur at the same time, and the same interactive response 
technology (IRT) will be used for both studies.  
Eligible subjects will be random ly assigned in a 1:1 ratio to perform self -injection using either 
the bimekizumab -SS-1mL or the bimekizumab -AI-1mL (see Section  7.10). Subjects will  
perform self -injection with the assigned device presentation at Baseline (corresponding to the 
Entry Visit of PA0012) and at Week  4 (corresponding to Week  4 of PA0012).  
At Baseline, Week 4, and Week 8 (of PA0012), pre -injection blood samples for PK trough  
analysis will be collected. At Baseline and Week 4, subjects will self -inject 160mg bimekizumab 
using the assigned device presentation. Bimekizumab PK trough levels associated with injection 
by study personnel using the 1mL PFS (in PA0010 or PA0011) will be analyzed from the 
pre-injection PK sample collected at Baseline.  Bimekizumab PK trough levels associated with 
subject self -injection using the assigned self -injecting device presentation will be analyzed from 
the pre -injection PK samples collected at We ek 4 and Week 8 (of PA0012).  
In addition to self -injections, DV0004 substudy -specific assessments (eg, study personnel 
evaluation of safe and effective self -injection, VAS for injection site pain, SIAQ responses, and 
PK analyses; see Section  5.2) will be performed from Baseline through Week  4 (inclusive). An 
SFU telephone call will occur 1  week after the last self -administration in DV0004.  
After Week 5  of the DV0004 substudy, subjects will continue in PA0012 (the next visit after 
DV0004 completion will be the Week 8 Visit in PA0012). At Week  8 in PA0012, study 
personnel qualified in sc injection technique will administer bimekizumab to subjects in a 1mL  
PFS, or the subject/caregiver/appropriate designee will perform administration under the 
supervision of the site staff after training . Studies DV0004 and PA0012 will share a common 
database/electronic Case Report form  (eCRF) system (including common adver se event [AE] 
reporting) and a common IRT.  
Subjects who are withdrawn from DV0004 but continue their PA0012 study participation will be 
required to perform an SFU telephone call 1 week after their final DV0004 dosing visit (see 
Section  6.3). Subjects who are withdrawn from bimekizumab treatment (PA0012 study) during 
the course of DV0004 will also be required to follow the PA0012 withdrawal procedures.  
5.1.1  Study duration per subject  
The maximum DV0004 substudy duration will be 5 weeks for each subject. Subjects will then 
continue to receive treatment in PA0012 for the duration of the PA0012 study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 17 of 49 The end of the DV0004 substudy is defined as the date on whic h the last subject completes 
his/her Week  5 Visit or withdraws from the study.  
5.1.2  Planned number of subjects and sites  
It is planned to enroll approximately 200 subjects; each device presentation arm will consist of 
approximately 100  subjects. It is anticipat ed that this study will involve up to 150 sites in North 
America and Europe.  
5.1.3  Anticipated regions and countries  
This substudy will be conducted in North America and Europe.  
5.2 Schedule of study assessments  
The schedule of assessments for DV0004 is presented in  Table  5‒1 and includes assessments 
performed specifically in the DV0004 substudy. The schedule of assessment for PA0012 Entry 
Visit through Week 8 is p resented in Table  5‒2 and includes assessments performed as part of 
the PA0012 study.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 18 of 49 Table  5‒1: Schedule of study assessments for DV0004  
Visit a 
Week 
 
 
Procedures  Visit 1  Visit 2  Visit 2a  
Telephone Call  
(Device SFU)  
Baseline/ Feeder Study 
Final Visit  Week 4 Week 5  
Informed consent for DV0004 assessments  X   
Inclusion/exclusion  X   
Concomitant medication X X X 
Adverse events b X X X 
Random assignment to device presentation  X   
IRT contact  X X X 
Subject training for VAS and SIAQ Questionnaire  X   
Pre-injection SIAQ Questionnaire c X   
Subject training for self -injection  X   
Subject self -injection of bimekizumab using the 
assigned device presentation  X X  
Study personnel evaluation of self -injection  X X  
Study personnel evaluation of post -use device 
presentation for visual signs of structural or mechanical 
integrity (such as cracks or loose parts) d X X  
VAS for injection site pain  X X  
Post-injection SIAQ Questionnaire c X X  
Drug and device presentation accountability  X X  
IRT=interactive  response technology; SFU=safety follow -up; SIAQ=Self -injection Assessment Questionnaire; VAS=visual analog scale  
a Visit windows are ±7 days from the scheduled visit day (relative to the first dose) at all visits except Visit 2a (SFU telephone call). The SFU telephone call 
window is 7 days from the last dose in the DV0004 substudy, ±3 days.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 19 of 49 Table  5‒1: Schedule of study assessments for DV0004  
Visit a 
Week 
 
 
Procedures  Visit 1  Visit 2  Visit 2a  
Telephone Call  
(Device SFU)  
Baseline/ Feeder Study 
Final Visit  Week 4 Week 5  
b Adverse events not related to the device presentations will be reported in PA0012 and adverse device effects and device defic iencies will be reported in 
DV0004. A sin gle safety database will be used for both studies.  
c Version 2.0 of the SIAQ will be used to assess bimekizumab -SS-1mL, while version 2.1 will be used to assess bimekizumab -AI-1mL (see Section  9.1). 
d Device presentations with visual signs of compromised structural or mechanical integrity should be returned to UCB after use.  Used device presentations 
that functioned as intended (ie, complete dose deli vered, no visual signs of compromised structural or mechanical integrity) should be stored at room 
temperature in a secured area and may only be destroyed following UCB’s instruction . 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 20 of 49 Table  5‒2: Schedule of study assessments for corresponding visits in PA0012  
Visit a 
Week 
 
Procedures  Visit 1  Visit 2  Visit 3  
Entry Visit/ Feeder Study 
Final Visit  Week 4  Week 8 
Informed consent PA0012 assessments  X   
Inclusion/exclusion  X   
Concomitant medication  X X X 
PHQ -9 X   
eC-SSRS  X X X 
Body weight  X   
Vital signs (pulse, temperature, BP) b X X X 
ECG by central reader  X   
Hematology/biochemistry/urine pregnancy c, d X X X 
Blood Sample for hs -CRP d X X X 
Blood sample for bimekizumab plasma concentrations c, d X X X 
Blood sample for anti -bimekizumab antibodies d X X X 
IGRA TB test  X e   
TB questionnaire  X   
Physical examination f X   
BSA affected by PSO (BSA palm method)  X   
PASI g X   
IGA g X   
TJC (68) and SJC (66)  X   
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 21 of 49 Table  5‒2: Schedule of study assessments for corresponding visits in PA0012  
Visit a 
Week 
 
Procedures  Visit 1  Visit 2  Visit 3  
Entry Visit/ Feeder Study 
Final Visit  Week 4  Week 8 
HAQ -DI X   
PtAAP  X   
PhGA -PsA X   
PhGA -Arthritis  X   
PGA -PsA X   
PGA -Arthritis  X   
BASDAI  X   
mNAPSI  X   
LEI/SPARCC  X   
LDI  X   
PSAID -12 X   
FACIT -F X   
SF-36 X   
EQ-5D-3L X   
WPAI -SHP X   
Adverse events h X X X 
IRT contact  X X X 
Bimekizumab administration by study personnel using 
the PFS    X 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 22 of 49 Table  5‒2: Schedule of study assessments for corresponding visits in PA0012  
Visit a 
Week 
 
Procedures  Visit 1  Visit 2  Visit 3  
Entry Visit/ Feeder Study 
Final Visit  Week 4  Week 8 
BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BP=blood pressure; BSA=body surface area; ECG=electrocardiogram; eC -SSRS=electronic 
Columbia Suicide Severity Rating Scale; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions 3 -level; FACIT -F=Functional Assessment of Chronic Illness 
Therapy —Fatigue; HAQ -DI=Health Assessment Questionnaire -Disability Index; hs -CRP=high sensitivity C -reactive protein; IGA=Investigator’s Global 
Assessment; IGRA=interferon -gamma release assay; IRT=interactive response technology; LDI=Leeds Dactylitis Index; LEI=Leeds Enthesitis I ndex; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area Severity Index; PGA -Arthritis=Patient’s Global Assessment of Arthritis; 
PGA -PsA=Patient’s Global Assessment of Psoriatic Arthritis; PhGA -Arthritis=Physician’s Global Assessment of Art hritis; PhGA -PsA=Physician’s Global 
Assessment of Psoriatic Arthritis; PHQ -9=Patient Health Questionnaire  9; PsAID=Psoriatic Arthritis Impact of Disease; PSO=psoriasis; PtAAP=Patient’s 
Assessment of Arthritis Pain; Q4W=every 4 weeks; SF -36=Short Form 36 -item Health Survey; SFU=safety follow -up; SIAQ=Self -injection Assessment 
Questionnaire; SJC=swollen joint count; SPARCC=Spondyloarthritis Research Consortium of Canada; TB=tuberculosis; TJC=tender j oint count; 
VAS=visual analog scale; WPAI -SHP=Work Productiv ity and Activity Impairment Questionnaire -specific health problem  
a Visit windows are ±7 days from the scheduled visit day (relative to the first dose) at all visits  with a minimum of 21 days and a maximum of 35 days in 
between bimekizumab doses . 
b Adverse  events not related to the device presentations will be reported in PA0012 and adverse device effects and device deficiencies will be reported in 
DV0004. A single safety database will be used for both studies.  
c If there has been a delay in menses, perform  a urine pregnancy test.  
dAll blood samples are to be taken prior to bimekizumab dosing.  
e This assessment only needs to be performed at study entry if an IGRA negative result is not available from less than 6 weeks prior to the first dose of open 
label bi mekizumab.  
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB.  
g If the BSA affected by PSO was ≥3% at Baseline from PA0010 or PA0011, determine the PASI and IGA.  
h Adverse events not related to the device presentations will be reported in PA0012 and adverse device effects and device deficiencies will be reported in 
DV0004. A single safety database will be used for both studies.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 23 of 49 5.3 Schematic diagram  
The study schematic diagram for DV0004 is presented in Figure  5‒1. 
Figure  5‒1: Schematic diagram  
 
OLE=open -label extension; Ph3=P hase 3; PK=pharmacokinetic; W=Week  
Note: The DV0004 substudy ends after the Week 5 SFU phone call. The Week 8 pre -injection PK sample is 
collected in PA0012.  
5.4 Rationale for study design and selection of dose  
DV0004 is a Phase 3, multicenter, open -label, ran domized, noncomparator, North America and 
Europe substudy to PA0012 for subjects with PsA who will self -inject bimekizumab. PA0012 is 
a multicenter, open -label, long -term study to evaluate the safety, tolerability, and efficacy of 
bimekizumab in subjects w ith PsA who complete 1  of the Phase  3 feeder studies (PA0010, 
PA0011).  
It is expected that most individuals who will use commercial bimekizumab for the treatment of 
PsA will self -inject bimekizumab and also that these individuals will prefer to have option s for 
the self -administration of their medication. DV0004 will therefore evaluate the safe and effective 
use of 2 different self -injecting device presentations: bimekizumab -SS-1mL and 
bimekizumab -AI-1mL. In addition, DV0004 will assess trough PK levels ass ociated with 
self-injection using the test self -injecting device presentation, injection by study personnel using 
the 1mL PFS, injection site (abdomen or thigh), by anti -bimekizumab antibody status, and BMI 
category (by tertile).  
6 SELECTION AND WITHDR AWAL OF SUBJECTS  
6.1 Inclusion criteria  
To be eligible for DV0004, subjects must meet all of the following criteria:  
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form (ICF) for DV0004 is signed and dated by the subject.  
2. Subject fulfills all inclusion criteria for the PA0012 study.  
3. Subject is considered reliable and capable of adhering to the DV0004 protocol (eg, able to 
understand and complete questionnaires, able to use investigational self-injecting devi ce 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 24 of 49 presentation  according to the IFU, and able to adhere to the visit schedule) according to the 
judgment of the Investigator.  
4. Subject is willing to self -inject.  
6.2 Exclusion criteria  
Subjects are not permitted to enroll in DV0004 if any of the PA0012 study e xclusion criteria are 
met. 
6.3 Withdrawal criteria  
Since DV0004 is a substudy of PA0012, all DV0004 withdrawal criteria are captured in the 
PA0012 protocol. There are no additional DV0004 -specific withdrawal criteria beyond those that 
are described in PA0012. Subjects are free to withdraw from DV0004 at any time, without 
prejudice to their continued care. Subjects who withdraw from DV0004 but remain eligible for 
PA0012 (ie,  subjects who have a medical condition or personal preference that precludes further 
self-injection) may continue in PA0012. These subjects must perform an SFU telephone call 
1 week after their last self -injection in DV0004.  
Subjects who are withdrawn from bimekizumab treatment during DV0004 will also be required 
to follow the PA0012 withdrawa l procedures.  
7 INVESTIGATIONAL MEDI CINAL PRODUCT AND 
INVESTIGATIONAL DEVI CE 
In the DV0004 substudy, the term IMP refers to the bimekizumab drug product. The term 
investigational self-injecting device presentation  refers to 2 different investigational 
self-injecting device presentation s (bimekizumab -SS-1mL and bimekizumab -AI-1mL) that are 
comprised of  drug product (IMP) associated with a functional secondary packaging . 
7.1 Description of device presentations  
At DV0004 Baseline, each subject will be provided with self-injection training and the IFU for 
the appropriate device presentation.  
7.1.1  Bimekizumab -SS-1mL 
The bimekizumab -SS-1mL, shown in Figure  7-1, consists o f the naked PFS (primary packaging 
containing bimekizumab drug product for all Phase 3 studies) and a customized  
safety syringe for sc bimekizumab administration.  
The naked PFS is a glass, 1mL long, primary container with small round flange and a 27G 
half-inch staked needle containing 1mL of bimekizumab. The  safety syringe is a 
single -use platform device with a passive needle stick safety mechanism. To enhance the device 
usability, UCB has customized the external components including adding an 
over-cap and modifying the extended finger flange and plunger rod.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 27 of 49 7.3 Packaging  
The site will receive uniquely -numbered device presentations (bimekizumab -SS-1mL and 
bimekizumab -AI-1mL)  for use in the DV0004 substudy.  
7.4 Labeling  
Clinical drug and device presentation supplies will be labeled in accordance with the current 
International Council for Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and 
Good Manufacturing Practice  and will include any locally required statements. If necessary, 
labels will be translated into the local language.  
7.5 Handling and storage requirements  
The device presentation that houses the naked PFS including IMP must be securely stored at 
2ºC to 8ºC (ie,  in a refrigerator), that is either in a locked room or in the pharmacy. Appropriate 
storage conditions must be ensured by controlling refrigerator temperature by using either an 
automated temperature monitoring and recording system or a minimum/maximum th ermometer 
and completing a daily temperature log in accordance with local requirements. If an out -of-range 
temperature is noted, the Sponsor or designee must be notified so that a determination can be 
made whether the product should be used or not.  
The Inv estigator or hospital pharmacist is responsible for the appropriate storage and 
accountability of the device presentation at the site, as well as, for the documentation of 
appropriate storage and accountability. Refer to the IMP Handling Manual for additio nal 
information on handling and storage requirements.  
7.6 Drug and device presentation accountability  
The Investigator will receive numbered treatments that will be assigned to eligible subjects by an 
IRT at Baseline. All IMP administrations will be observed b y the Investigator or his/her 
appropriately trained designee.  
Appropriate accountability forms that reflect the receipt and use of the IMP and the device 
presentations will be supplied to the investigational site. Details of any loss of the self -injection 
device presentations due to breakage or wastage, non -use, destruction at the study site, or return 
to the Sponsor or designee must also be recorded on these forms. All supplies and pharmacy 
documentation must be made available throughout the study for UCB (or designee) to review.  
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
IMP and device presentations until returned to UCB. Used or partially used devices are to be 
stored at room temperature in a secured a rea and may only be destroyed following UCB’s 
instruction. Devices with noted deficiencies (see Section  11.1.1.3 ) are to be returned to UCB 
immediately. The Investigator may assign some of the Investigator’s duties for drug 
accountability at the study site to an appropriate pharmacist/designee.  
The IMP and device presentations intended for the study cannot be used for any other purpose 
than th at described in this protocol.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 28 of 49 7.7 Procedures for monitoring subject compliance  
During the Treatment Period of this study, IMP administration (self -administration) will be 
performed in the clinic and observed by the Investigator or his/her designee; monitoring  subject 
compliance is therefore not applicable.  
7.8 Concomitant medications/treatments  
Any specifications given in PA0012 regarding permitted and prohibited concomitant medications 
must be followed.  
7.8.1  Permitted concomitant treatments (medications and therapies)  
Unless otherwise specified in PA0012, subjects are permitted to continue their prescribed 
medical therapy for the disease in accordance with the instructions of their treating physician. 
Concomitant medications and therapies, including over -the-counter pr oducts and supplements, 
must be recorded in the subject’s notes (source documentation) and provided on the eCRF. This 
record should include the name of the drug, the dose, the route and date(s) of administration, and 
the indication for use.  
7.8.2  Prohibited conc omitant treatments (medications and therapies)  
In addition to the prohibited treatments described in PA0012, subjects are not permitted to use 
topical analgesics at the injection site at Baseline or Week 4 in the DV0004 substudy.  
7.9 Blinding  
This is an open -label substudy.  
7.10 Randomization and numbering of subjects  
The same unique 5 -digit identification number used in the feeder study will be used in PA0012 
and in substudy DV0004. This subject number will be used to identify the subject throughout 
PA0012 and DV00 04 and to maintain subject confidentiality. At study visits, an IRT will assign 
the applicable subject kits of IMP. Further instructions will be provided in the IRT manual.  
The IRT will generate individual assignments for the self -injection device presenta tions. Eligible 
subjects will be assigned to the device presentations based on a predetermined production 
randomization and/or packaging schedule provided by UCB (or designee). All eligible subjects 
will be randomly assigned to perform self -injection using  either the bimekizumab -SS-1mL or the 
bimekizumab -AI-1mL at a 1:1 ratio. The IRT will allocate kit numbers to the subject based on 
the subject number during the study.  
Subject numbers and kit numbers will be tracked via the IRT.  
8 STUDY PROCEDURES BY VISIT  
A general overview of the study assessments is provided in Table  5‒1 and Table  5‒2. Of note, 
DV0004 and PA0012 will share a common database/eCRF system (including common AE 
reporting) and a common IRT.  
The following visit windows are permitted:  
• As in PA0012, a 7 -day visit window on either side of the sc heduled dosing is permitted; 
however, the Investigator should try to keep the subjects on the original dosing schedule. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 29 of 49 Changes to the dosing schedule outside of the 7 -day window must be discussed with the 
Medical Monitor.  
• The SFU telephone call should occ ur within 7 days after the last dose in the DV0004 
substudy, ±3 days.  
8.1 Treatment Period  
The DV0004 substudy will include all PA0012 study assessments from Baseline to Week  4 
(inclusive). All study procedures and assessments will be performed in accordance w ith 
Table  5‒1 and Table  5‒2. 
8.1.1  Unscheduled Visit  
At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the 
study but prior to the SFU Visit, if deemed necessary for the subject’s safet y and well -being.  
At this visit, any of the following assessments may be performed, depending on the reason for 
the visit:  
• Record concomitant medication  
• Record AEs  
• If medically indicated, other assessments that are performed in PA0012 may be performed  
9 ASSE SSMENT OF SELF -INJEC TION  
Evaluation of dose delivery and safe self -injection will be performed as described for the primary 
outcome variable ( Section  4.1.1 ). 
9.1 Assessment of injection site pain  
A VAS will be used to assess overall injection pain due to self -injection at Baseline and at 
Week  4. Subjects will be required to indicate their injection pain by placing a mark on a 100mm 
line from 0 (no pain) to  100 (worst possible pain). The subject will complete the VAS prior to 
completion of the post -injection SIAQ (refer to Section  9.1 for details).  
9.2 Assessment of self -injection experience by SIAQ  
The SIAQ will be used to assess the subject’s self -injection experience.  
The SIAQ was developed by UCB to assess the perceived advantages and the potential 
limitations of self -injection of an  sc medication (K eininger and Coteur, 2011). The pre -injection 
SIAQ is composed of 7 items grouped into 3  domains (feelings about injection, self -confidence, 
and satisfaction with the current mode of administration). The post -injection SIAQ is composed 
of 21  items grouped into 6  domains (feelings about injection, self -image, self -confidence, 
injection site reactions, ease of use, and satisfaction with self -injection). T he pre -injection SIAQ 
will be completed at Baseline and the post -injection SIAQ will be completed within 3 0 minutes 
after each self -injection (ie, at Baseline and Week 4).  
Version  2.0 and version 2.1 of the SIAQ are identical, except for Question  11. In version 2.0 of 
the SIAQ, Question 11 discusses the use of a plunger, while in version  2.1 of the SIAQ, 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 30 of 49 Question11 discusses depression of the device. Version 2.0 will therefore be used to assess 
bimekizumab -SS-1mL, while version  2.1 will be used to assess bimekizumab -AI-1mL.  
9.3 Evaluation of post -use structural, mechanical, and functional 
integrity of self -injecting device presentations  
Visual inspection of the used bimekizumab -SS-1mL and bimekizumab -AI-1mL devices will be 
performed by appropriately trained site staff to check for any signs of compromised structural or 
mechanical integrity (ie,  clear evidence o f damage, such as cracks or loose parts, and not any 
superficial, cosmetic imperfections, such as scratches or smudges, which have no impact on 
structural or mechanical integrity). Any device with compromised structural or mechanical 
integrity will be retu rned to UCB for further evaluation. The bimekizumab -SS-1mL and 
bimekizumab -AI-1mL have a lockout feature, which is activated upon completion of the 
injection and which ensures the needle guard is in position permanently to prevent post -use 
needle stick inj uries. Devices determined to not have the lockout feature in place, as detailed in 
the IMP Handling Manual, will be packaged and returned to UCB for further evaluation.  
10 ASSESSMENT OF PHARMA COKINETIC AND 
IMMUNOLOGICAL VARIAB LES 
Blood samples for measurement  of trough bimekizumab PK and anti -bimekizumab antibodies 
(Section  4.1.3 ) will be collected at the time points specified in the schedule of study as sessments 
(Table  5‒1 and Table  5‒2). 
At dosing v isits, blood samples will be drawn prior to dosing (at the same time of the sampling 
for clinical laboratory tests in PA0012). The time and date of collection will be recorded in the 
eCRF.  
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual (for PA0012). Detailed information on sample analysis will be 
provided in a bioanalytical report.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 31 of 49 11 ASSESSMENT OF SAFETY  
11.1 Adverse events (device presentations)  
All AEs (including serious adverse eve nts [SAEs]) will be reported in a common database for 
PA0012 and DV0004, but only ADEs, SADEs, and device deficiencies will be summarized in 
the DV0004 substudy. Specifically, only those AEs related to the use of the device presentations  
bimekizumab -SS-1mL or bimekizumab -AI-1mL (based on the Investigator’s judgement) will be 
assessed. All AEs (including SAEs) which are not assessed to be related to the device 
presentations  will be summarized separately in the report for the main study, PA0012; please 
refer to the PA0012 protocol for information on reporting and recording AEs (including SAEs).  
11.1.1  Definitions (device presentations)  
11.1.1.1  Adverse device effect (device presentations)  
An ADE is an AE related to the use of a device presentation. An ADE must meet 1  or more of 
the following criteria:  
• Adverse event resulting from insufficiencies or inadequacies in the IFU, the deployment, the 
implantation, the installation, the operation, or any malfunction of the investigational medical 
device.  
• Adverse event that is a result of a use error or intentional misuse of the device presentation.  
11.1.1.1.1  Unanticipated adverse device effect  
An unanticipated ADE is an ADE which by its nature, incidence, severity, or outcome has not 
been previously identified.  
11.1.1.2  Serious adverse device effects  
A SADE is an ADE that has resulted in any of the consequences characteristic of an SAE.  
An SAE (and therefore a SADE) must meet 1 or more of the following criteria:  
• Death  
• Life-threatening  
(Life -threatening does not include a reaction that might have caused d eath had it occurred in 
a more severe form.)  
• Significant or persistent disability/incapacity  
• Congenital anomaly/birth defect (including that occurring in a fetus)  
• Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious  
(Important medical events may include, but are not limited to, potential Hy’s Law, allergic 
bronchospasm requiring in tensive treatment in an emergency room or at home, blood 
dyscrasias that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse.)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 32 of 49 • Initial inpatient hospitalization or prolongation of hospitalization  
(A patient admit ted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization crit eria. 
However, emergency room visits that do not result in admission to the hospital would not 
qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg,  life-threatening adverse experience, im portant medical event].  
Hospitalizations for reasons not associated with the occurrence of an AE [eg,  preplanned 
surgery or elective surgery for a pre -existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not q ualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon w hich to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be dete rmined.)  
11.1.1.2.1  Anticipated and unanticipated serious adverse device effects  
An anticipated SADE is a SADE which by its nature, incidence, severity, or outcome has been 
identified in the risk analysis report (ISO 14155).  
An unanticipated serious adverse device ef fect (USADE) is a SADE which by its nature, 
incidence, severity, or outcome has not been identified in the current version of the risk analysis 
report.  
The Sponsor will determine if a SADE qualifies as an USADE. The Sponsor will also evaluate 
all SADEs to ensure that expedited reporting requirements are met according to UCB Standard 
Operating Procedures (SOPs) and applicable country -specific regulatory requirements for the 
device presentation.  
11.1.1.3  Device deficiency (device presentations)  
A device deficiency is an inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety, or performance. Device deficiencies include malfunctions, use 
errors, and inadequate labeling.  
11.1.2  Procedures for reporting and recording adverse device e ffects and 
device deficiencies  
The subject will be given the opportunity to report ADEs, SADEs, and device deficiencies 
spontaneously. A general prompt will also be given at each study visit to detect AEs that qualify 
as ADEs, SADEs, and device deficiencie s. Below is an example prompt:  
“Did you notice anything unusual about the injection?”  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 33 of 49 11.1.2.1  Reporting of adverse device effects  
All ADEs and SADEs will be captured on the eCRF. The eCRF will allow Investigators to 
specify whether an AE or SAE is device -related a nd will clarify which device presentation is 
associated with the ADE or SADE.  
An Investigator Adverse Device Effect and Device Deficiency form will be provided to the 
Investigator. The Investigator Adverse Device Effect and Device Deficiency form must be 
completed in English.  
The Investigator (or designee) shall report all SADEs and device deficiencies that might have led 
to an SAE (if suitable action had not been taken, if intervention had not been made, or if 
circumstances had been less fortunate) to UCB within 24 hours after knowledge of the event 
using the appropriate forms in the electronic data capture system. When required by national or 
local regulations, the Investigator shall also notify the IRB/IEC and regulatory agencies of all 
reportable events according to national regulations in acceptable timely conditions, and may also 
be requested by the IRBs to provide annual reports.  
11.1.2.2  Reporting of device deficiencies  
If a device deficiency related to the identity, quality, durability, reliability, safety, o r performance 
of the device presentation is reported (even if the device presentation was not used), UCB must 
be informed within 1 business day (within 24 hours, as a rule) of receipt of this information by 
the site. The Investigator must forward to UCB (o r designee) a duly completed Investigator 
Adverse Device Effect and Device Deficiency form provided by UCB, even if the data are 
incomplete or if it is obvious that more data will be needed to draw any conclusions.  
An Investigator Adverse Device Effect and  Device Deficiency form will be provided to the 
Investigator. The Investigator Adverse Device Effect and Device Deficiency form must be 
completed in English.  
It is important for the Investigator, when completing the Investigator Adverse Device Effect and 
Device Deficiency form, to include an assessment and documentation of whether the device 
deficiency could have led to an SAE if any of the following occurred:  
• Suitable action had not been taken, or  
• Intervention had not been made, or  
• Circumstances had been less fortunate.  
All defective devices must be returned to UCB according to standard procedures (see 
Section  7.6). 
11.1.2.3  Reporting of serious adverse device  effects including device 
deficiencies with risk of serious adverse event  
If a device deficiency that could have led to an SAE (if suitable action had not been taken, or 
intervention had not been made, or circumstances had been less fortunate) is reported,  UCB must 
be informed within 24 hours of receipt of this information by the site (see contact information for 
SAE reporting listed in the Serious Adverse Event Reporting section at the front of the protocol). 
The Investigator must forward to UCB (or design ee) a duly completed “Investigator SAE Report 
Form for Investigational Medical Devices” provided by UCB, even if the data are incomplete, or 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 34 of 49 if it is obvious that more data will be needed to draw any conclusions. Information recorded on 
this form will be e ntered into the global safety database.  
An Investigator SAE Report Form for Investigational Medical Devices will be provided to the 
Investigator. The Investigator SAE Report Form for Investigational Medical Devices must be 
completed in English.  
Additional information (eg,  autopsy or laboratory reports) received by the Investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document mu st be 
summarized in the Investigator SAE Report Form for Investigational Medical Devices.  
The Investigator is specifically requested to collect and report to UCB (or designee) any ADEs 
or SADEs up to completion of the follow -up visit/telephone call for eac h subject, and to also 
inform participating subjects of the need to inform the Investigator of any ADEs or SADEs 
within this period. Serious AEs that the Investigator thinks may be associated with the device 
presentation must be reported to UCB regardless of the time between the event and the end of the 
study.  
Upon receipt of the Investigator SAE Report Form for Investigational Medical Devices, UCB 
will perform an assessment of whether the SADE is anticipated based on the current version of 
the risk analysi s report.  
11.1.2.4  Rule for repetition of an adverse device effect, serious adverse 
device effect, and/or device deficiency  
An increase in the intensity of an ADE or SADE should lead to the repetition of the ADE or 
SADE being reported with:  
• The outcome date of the first ADE or SADE that is not related to the natural course of the 
disease being the same as the start date of the repeated ADE or SADE, and the outcome of 
“worsening.”  
• The ADE or SADE verbatim term being the same for the first and repeated ADE or SADE, 
so that the repeated ADE or SADE can be easily identified as the worsening of the first one.  
11.1.3  Follow up of adverse device effects and serious adverse device 
effects  
All ADEs and SADEs should be followed until they have resolved, have stable sequelae, the 
Investigator determines that they are no longer clinically significant, or the subject is lost to 
follow up.  
If an ADE or SADE is ongoing at the end of the study for a subject, follow up should be 
provided until resolution/stable level of sequelae is achieved,  or until the Investigator no longer 
deems that it is clinically significant, or until the subject is lost to follow up. If no follow up is 
provided, the Investigator must provide a justification.  
Information on SADEs obtained after clinical database lock will be captured through the Patient 
Safety (PS) database without limitation of time.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 35 of 49 11.2 Pregnancy  
All events of pregnancy or partner pregnancy will be followed and documented as described in 
the PA0012 protocol.  
11.3 Suspected transmission of an infectious agent  
For the purposes of reporting, any suspected transmission of an infectious agent via medicinal 
products (device presentations or IMP) should be considered as an SAE or SADE; such cases 
must be reported immediately, recorded in the Adverse Event module of t he eCRF, and followed 
as any other SAE or SADE. Any organism, virus, or infectious particle (eg,  prion protein 
transmitting transmissible spongiform encephalopathy), pathogenic or nonpathogenic, is 
considered an infectious agent.  
There is no evidence that there is a risk of transmission of an infectious agent with the device 
presentations.  
11.4 Overdose of investigational medicinal product  
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SADE or  nonserious ADE associated with excessive dosing must be 
followed as any other SADE or nonserious ADE. These events are only considered ADEs or 
SADEs if there are associated clinical signs and symptoms or if the act of taking the excess 
medicine itself is an ADE or SADE (eg, suicide attempt).  
There is no evidence that there is a risk of overdose with the IMP when used with the device 
presentations.  
11.5 Safety signal detection  
Selected data from this study will be reviewed periodically to detect, as early as pos sible, any 
safety concern(s) related to the IMP or the device presentation so that Investigators, clinical 
study subjects, regulatory authorities, and IRBs will be informed appropriately and as early as 
possible.  
The Study Physician (or medically qualified  designee/equivalent) will conduct an ongoing 
review of SADEs and will perform ongoing SADE reconciliations in collaboration with the PS 
representative. Serious AEs not related to a device will be reported in PA0012.  
As appropriate for the stage of develop ment and accumulated experience with the IMP and the 
device presentation, medically qualified personnel at UCB may identify additional safety 
measures (ie, vital signs) for which data will be periodically reviewed during the study.  
11.6 Other safety measurement s 
11.6.1  Vital signs measurement  
No vital sign assessments will be performed for the DV0004 substudy. The vital sign 
assessments presented in Table  5‒2 will be  captured as part of the PA0012 study and are 
described in the PA0012 protocol.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 36 of 49 12 EFFICACY ASSESSMENTS  FOR PA0012  
No efficacy assessments will be performed for the DV0004 substudy. The efficacy assessments 
presented in Table  5‒2 will be captured as part of the PA0012 study and are described in the 
PA0012 protocol.  
13 STUDY MANAGEMENT AND  ADMINISTRATION  
13.1 Adherence to protocol  
The Investigator should not deviate from the DV0004 protocol or the PA0012 protocol. 
However, the Investigator should take any measure necessary, in deviation from or not defined 
by the protocol, in order to protect clinical study subjects from any immediate hazard to their 
health and safety . In this case, this action should be taken immediately, without prior notification 
of the regulatory authority,  IRB, or Sponsor.  
After implementation of such measure, the Investigator must notify the Clinical Project Manager 
of the Sponsor within 24  hours  and follow any local regulatory requirements.  
13.2 Monitoring  
UCB (or designee) will monitor the study to meet the Sponsor’s monitoring SOPs, ICH -GCP 
guidelines, and applicable regulatory requirements, and to ensure that study initiation, conduct, 
and closure are adequate. Monitoring of the study may be delegated by UCB to a contract 
research organization (CRO) or a contract monitor.  
The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring vis its to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
data/documents for study -related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).  
The Inves tigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg,  hospital and laboratory records for each study participant). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the  progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities’ regulations, and Investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records.  
13.2.1  Definition of source data  
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by corr ection fluid or have temporary attachments 
(such as removable self -stick notes).  
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x -rays, laboratory  results, printouts, 
pharmacy records, care records, electrocardiogram (ECG) or other printouts, completed scales, 
or quality of life questionnaires, for example. Source documents should be kept in a secure, 
limited access area.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 37 of 49 Source documents that are c omputer generated and stored electronically must be printed for 
review by the monitor (eg,  ECG reports). Once printed, these copies should be signed and dated 
by the Investigator and become a permanent part of the subject’s source documents. The 
Investigat or will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.  
Electronic data records, such as Holter monitor records or electroencephalogram records, m ust 
be saved and stored as instructed by UCB (or designee).  
13.2.2  Source data verification  
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to being accurate, complet e, and verifiable from 
source documents (eg,  subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory notes). All data reported on the eCRF should be supported by source 
documents, unless otherwise specified in Section  13.2.1 . 
13.3 Data handling  
13.3.1  Case Report form completion  
This study is performed using remote data capture. The Investigator is responsible for prompt 
reporting of accurate, complete, and legible data in the eCRFs and in all required reports.  
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.  
Corrections made after the Investigator’s review and approval (by mean s of a 
password/electronic signature) will be reapproved by the Investigator.  
The Investigator should maintain a list of personnel authorized to enter data into the eCRF.  
Detailed instructions will be provided in the eCRF Completion Guidelines.  
13.3.2  Database entry and reconciliation  
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used, in addition to manual review, to  check for discrepancies and to ensure consistency 
of the data. The data are entered into the eCRFs once and are subsequently verified.  
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the d ata have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 38 of 49 13.3.3  Subject Screening and Enrollment log/Subject Identification Code list  
The subject’s screening and enrollment will be recorded in the Subject Screening and 
Enrollment  log. 
The Investigator will keep a Subject Identification Code list. This list will remain with the 
Investigator and be used for unambiguous identification of each subject.  
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.  
13.4 Termination of the study  
UCB reserves the right to temporarily suspend or prematurely discontinue this study  either at a 
single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quant ity. 
The study may also be temporarily suspended or prematurely terminated in either of the 
following situations:  
• Severe or serious injection site reaction (eg, bleeding, bruising, pain) that, in the opinion of 
the Investigator, the overseeing IRB, or the Sponsor, is likely to be seen in other enrolled 
subjects who have not yet been injected with bimekizumab.  
• Unexpected device presentation malfunction leading to a failed or incomplete injection, or 
resulting in an SAE that, in the opinion of the Investigato r, the overseeing IRB, or the 
Sponsor, is likely to be seen in other enrolled subjects who have not yet been injected with 
bimekizumab.  
If the study is prematurely terminated or suspended, UCB (or designee) will inform the 
Investigators/institutions and th e regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination o r suspension by the Sponsor or by the Investigator/institution, as specified by the 
applicable regulatory requirement(s). In addition, arrangements will be made for the return of all 
used or unused IMP and other material in accordance with UCB procedures f or the study.  
13.5 Archiving and data retention  
The Investigator will maintain adequate records for the study, including eCRFs, medical records, 
laboratory results, informed consent documents, drug dispensing and disposition records, safety 
reports, information  regarding participants who discontinued, and other pertinent data.  
All essential documents are to be retained by the Investigator until at least 2  years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2  years have elapsed since the 
formal discontinuation of clinical development of the IMP or device presentations. These 
documents should be retained for a longer period; however, if required  by the applicable 
regulatory requirement(s) or by an agreement with UCB (CPMP/ICH/135/95, 2002 
[Section  4.9.5]). The Investigator will contact UCB for authorization prior to the destruction of 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 39 of 49 any study records or in the event of accidental loss or destru ction of any study records. The 
Investigator will also notify UCB should he/she relocate or move the study -related files to a 
location other than that specified in the Sponsor’s trial master file.  
13.6 Audit and inspection  
The Investigator will permit study -related audits mandated by UCB, after reasonable notice, and 
inspections by domestic or foreign regulatory authorities.  
The main purposes of an audit or inspection are to confirm that the rights and well -being of the 
subjects enrolled have been protected, tha t enrolled subjects (ie,  signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP and the device presentations have been processed and reported in compliance with the 
planned a rrangements, the protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and 
applicable regulatory requirements.  
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory author ity is announced, the Investigator will immediately 
inform UCB (or designee).  
13.7 Good Clinical Practice  
Noncompliance with the protocol, ICH -GCP, or local regulatory requirements by the 
Investigator, institution, institution staff, or designees of the Sponsor  will lead to prompt action 
by UCB to secure compliance. Continued noncompliance may result in the termination of the 
site’s involvement in the study.  
14 STATISTICS  
A description of statistical methods follows and will be described in more detail in the Stati stical 
Analysis Plan (SAP).  
14.1 Definition of analysis sets  
Two different Safety Sets (SS) will be generated (1 for each device presentation): the 
bimekizumab -SS-1mL Safety Set (SS -s) and the bimekizumab -AI-1mL Safety Set (SS -a). Each 
SS will consist of all su bjects in the study who receive at least 1 dose of bimekizumab by the 
indicated self -injecting device presentations. Safety variables will be analyzed using the SS -s and 
SS-a. 
Two different Full Analysis Sets (FASs) will be generated (1 for each device presentation): the 
bimekizumab -SS-1mL Full Analysis Set (FAS -s) and the bimekizumab -AI-1mL Full Analysis 
Set (FAS -a). Each FAS will consist of all subjects in the SS -s or SS -a who self -inject at least 
1 dose of bimekizumab using the given device and who ha ve an assessment of self -injection. All 
self-injection related endpoints will be analyzed using the FAS-s and FAS -a. 
Two different Pharmacokinetic Sets (PKS) will be generated (1 for each device presentation): the 
bimekizumab -SS-1mL PKS (PKS -s) and the bim ekizumab -AI-1mL PKS (PKS -a). Each PKS 
will consist of all subjects who receive the same bimekizumab administration (frequency and 
dose) in the PA0012 feeder studies as in the DV0004 substudy and who have at least 1  evaluable 
PK assessment in the DV0004 sub study. Pharmacokinetic variables will be analyzed using the 
PKS-s and PKS -a. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 40 of 49 14.2 General statistical considerations  
This is an estimation study design with no formal statistical hypothesis testing. The study will 
estimate the true population proportion and/or mean of self -injection related endpoints for each 
device presentation separately. Summary statistics for continuous variables will include: number 
of available observations, mean, standard deviation, minimum, median, and maximum. For 
categorical variables,  the number and proportion of subjects, along with the 90% confidence 
interval  (CI) based on the Exact Binomial method, will be presented.  
The Baseline value is defined as the last nonmissing measurement prior to the first self -injection 
at Visit 1 (Baseli ne). No imputation of missing data will be performed. All data recorded in the 
eCRF and questionnaires will be listed.  
14.3 Planned analyses of outcome variables  
All statistical analyses will be descriptive in nature. No inferential statistical analyses are 
planned.  
14.3.1  Analysis of the primary outcome variable  
The primary outcome variable is the percentage of all subjects able to self -administer safe and 
effective injections using the given device presentation at Week  4. Safe and effective 
self-injection will be eva luated by the study personnel as defined in in Section  4.1.1 . 
The number and percentage of subjects with safe and effective self -injections will be tabulated 
separately for each device presentation overall using the relevant FAS population (FAS -s or 
FAS-a). The 90% CIs based on the Exact Binomial method will be reported as well.  
14.3.2  Analysis of the secondary outcome variable  
The secondary outcome variable  is the percentage of subjects able to self -administer safe and 
effective injections using the given device presentation at Baseline (the first self -injection visit, 
immediately after training in self -injection technique). Safe and effective self -injection  will be 
evaluated by the study personnel as defined in  Section  4.1.1 . 
The secondary outcome variables will be analyzed in the same manner as the pri mary outcome 
variable (see Section  14.3.1 ). 
14.3.3  Analysis of other outcome variables  
The other outcome variables are defined in Section  4.1.3 . These variables will be summarized 
using descriptive statistics and they will be tabulated separately for each device overall using the 
relevant FAS population (FAS -s or FAS -a). 
14.4 Planned pharmacokinetic analyses  
The statistical analyses of the PK data will be descriptive in nature and will be summarized using 
the relevant device presentation -specific population (PKS -s or PKS -a). Data will be analyzed 
overall for e ach device presentation by injection type (self -administered or study 
personnel -administered), by injection site (abdomen or thigh), by anti -bimekizumab antibody 
status, and by BMI category. Three BMI categories will be defined based on tertiles derived 
from subjects’ Baseline BMI values.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 41 of 49 To allow for an analysis of bimekizumab PK trough levels and anti -bimekizumab antibodies, 
blood samples will be taken before self -injection at the Baseline Visit (PK trough and 
anti-bimekizumab antibody analysis), Visit 2 Week 4 (PK trough analysis only), and Week 8 of 
PA0012 (PK trough and anti -bimekizumab antibody analysis). Anti -bimekizumab antibody 
status at or prior to the PK sampling (at Baseline, Week 4, and Week 8) will be used. The 
number and percentage of anti -bimekizumab antibody -positive and -negative subjects before 
self-injection (Baseline) and after self -injection (Week 8 of PA0012) will be summarized.  
Bimekizumab PK trough levels associated with injection by study personnel using the 1mL PFS 
(in PA0010 or PA0 011) will be analyzed from the pre -injection PK sample collected at Baseline. 
Bimekizumab PK trough levels associated with subject self -injection using the assigned self -
injecting device presentation will be analyzed from the pre -injection PK samples colle cted at 
Week 4 and Week 8 (of PA0012).  
For the analysis of PK trough levels by injection site (abdomen or thigh) and by BMI category 
(by tertile), only self -administration PK trough levels will be used.  
14.5 Planned safety analyses  
The safety variable is the oc currence of ADEs; additional safety and tolerability variables will be 
collected in PA0012 (see Section  4.1.3.4 ). Analyses of safety data will be don e separately for 
each device presentation overall and within each device presentation using the relevant SS 
population (SS -s or SS -a). 
All ADE data will be listed and no statistical testing will be performed. Only treatment -emergent 
ADEs will be included in the summary tables. All ADEs will be coded and classified by system 
organ class, high level term, and preferred term according to the Medical Dictionary for 
Regulatory Activities v19.0 . Adverse device effects will be summa rized by the frequency and 
percentage of subjects having 1 or more of the events in question. Additional planned summaries 
include overall ADEs and SADEs.  
14.6 Planned efficacy analyses  
No efficacy analyses are planned for the DV0004 substudy.  
14.7 Handling of proto col deviations  
Important protocol deviations are deviations from the protocol which could potentially have a 
meaningful impact on the primary objective of the study. The criteria for identifying important 
protocol deviations and the classification of impor tant protocol deviations will be defined within 
the project Data Cleaning Plan. To the extent feasible, the rules for identifying protocol 
deviations will be defined without review of the data and without consideration of the frequency 
of occurrence of suc h deviations. Whenever possible, criteria for identifying important protocol 
deviations will be implemented algorithmically to ensure consistency in the classification of 
important protocol deviations across all subjects.  
14.8 Handling of dropouts or missing da ta 
There will be no special procedures for handling missing data. All imputation of missing or 
partial dates for safety assessments will be detailed in the SAP.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 42 of 49 14.9 Planned interim analysis and data monitoring  
No interim analysis is planned for the DV0004 substudy.  
14.10  Determination of sample size  
This study will not be powered with respect to any endpoint, and sample size is based on 
practical considerations. In order to maintain blinding in the PA0012 feeder studies (PA0010 and 
PA0011), DV0004 will recruit al l subjects who complete the PA0010 and PA0011 feeder studies 
(including those treated with a comparator or placebo in the feeder study) up to a total of about 
200 subjects. A total of 100  subjects (50  subjects per device presentation arm) are planned for 
PK trough level analyses, but these analyses will only be performed on subjects who were treated 
with bimekizumab 160mg Q4W (ie, not with placebo or comparator) in the feeder studies prior 
to rolling over into the DV0004 substudy. The DV0004 substudy will e nroll approximately 
200 subjects (to compensate for subjects treated with placebo or comparator) to ensure that 
100 subjects with stable (160mg Q4W bimekizumab) PK trough levels are available for PK 
trough analysis.  
Subjects who enroll in the DV0004 substu dy will be randomly assigned to the 
bimekizumab -SS-1mL or the bimekizumab -AI-1mL device presentation  arms (each device 
presentation arm will consist of approximately 100 subjects). Within each device presentation 
arm, subjects will be divided into tertiles  by BMI; there will be approximately 33  subjects per 
tertile, which is expected to yield approximately 16 to 17  subjects per tertile who are evaluable 
for steady state trough PK level analyses.  
15 ETHICS AND REGULATOR Y REQUIREMENTS  
15.1 Informed consent  
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH -GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.  
Prior to obtaining informed consent, informatio n should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by the Investigator (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
the Investigat or. 
Prior to participation in the study, the ICF should be signed and personally dated by the subject 
and by the person who conducted the informed consent discussion (Investigator or designee). 
The subject must receive a copy of the signed and dated ICF. A s part of the consent process, 
each subject must consent to direct access to his/her medical records for study -related 
monitoring, auditing, IRB/IEC review, and regulatory inspection.  
If the ICF is amended during the study, the Investigator (or the Sponsor , if applicable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF by 
the IRB/IEC and use of the amended form.  
All studies conducted at centers in the US must include the use of a Health Insurance Portability 
and Accountability Act Authorization form.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 43 of 49 The subject may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the ICF. An eCRF must not be 
started, nor may any study -specific procedure be performed for a given subject, without having 
obtained his/her written consent to participate in the study.  
15.2 Subject identification cards  
Upon signing the ICF, the subject will be provided with a subject identification card in the 
languag e of the subject. The Investigator will fill in the subject identifying information and 
medical emergency contact information. The Investigator will instruct the subject to keep the 
card with him/her at all times.  
15.3 Institutional Review Boards and Independen t Ethics 
Committees  
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.  
The Investigator/UCB will ensur e that an appropriately constituted IRB/IEC, that complies with 
the requirements of the current ICH -GCP version or applicable country -specific regulations, will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copies of the protocol, ICF, 
Investigator’s Brochure, Investigator’s curriculum vitae (if applicable), advertisement (if 
applicable), and all other subject -related documents to be used for the s tudy to the IRB/IEC for 
its review and approval.  
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.  
The Investigator will also promptly report to the IRB/IEC all changes in t he study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.  
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, ex cept where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the Investigator to obtain an expedited review by t he IRB/IEC as 
allowed.  
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study 
completion.  
UCB (or designee) will communicate safety information to the appropriate regulatory authorities 
and all active Investigators in accordance with applicable regulatory requirements. The 
appropriate IRB/IEC will also be informed by the Investigator or the Sponsor, as specified by the 
applicable regulatory requirements in each concerned country. Where app licable, Investigators 
are to provide the Sponsor (or designee) with evidence of such IRB/IEC notification.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 44 of 49 15.4 Subject privacy  
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or d esignee) will be identified only by the subject number 
assigned at Visit  1. 
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a subject’s study partici pation, and autopsy reports for deaths 
occurring during the study).  
15.5 Protocol amendments  
Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study ful filling its primary 
objective.  
Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB, and the regulatory authorities (if required), prior to being 
implemented.  
16 FINANCE, INSURANCE, AND PUBLICATION  
Insurance coverage will be handled according to local requirements.  
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.  
17 REFERENCES  
CPMP/ICH/135/95 Note for guidance on Good Clinical  Practice (EMEA) Jul 2002.  
Keininger D, Coteur G. Assessment of self -injection experience in patients with rheumatoid 
arthritis: psychometric validation of the Self -Injection Assessment Questionnaire (SIAQ). 
Health  and Quality of Life Outcomes . 2011;9:2.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 45 of 49 18 APPENDICES  
18.1 Protocol Amendment 1  
The main purpose of this protocol amendment was to clarify study procedures and update the 
description of the IMP.  
Modifications and changes  
Global changes:  
The following changes were made throughout the protocol and are not included in specific 
changes section:  
• The company name was changed from UCB Biopharma SPRL to UCB Biopharma SRL  
• The term “legal representative” was deleted from protocol, as it is not applicable to DV0004 
or PA00012  
• Minor spelling, editorial, and formatti ng changes were made throughout the document  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 46 of 49 Specific changes:  
Protocol section 
impacted  Key components of previous 
protocol text  Key components of revised protocol 
text Rationale  
Change 1: Administrative section  
Study contact details    
UCB Celltech Ltd.  
208 Bath Road  
Slough SL1 3WE, UK  
   
UCB Celltech Ltd.  
208 Bath Road  
Slough SL1 3WE , UK  
UNITED KINGDOM  The country name was added.  
 
... 
  
... 
 The Clinical Project Manager has 
changed.  
 
UCB BIOSCIENCES Inc.  
8010 Arco Corporate Drive  
Raleigh, NC 27617  
UNITED STATES  
  
UCB BIOSCIENCES Inc.  
208 Bath Road  
Slough SL1  3WE  
UNITED KINGDOM  
 The Clinical Trial Biostatistician 
has changed.  
Change 2: Minor updates to Schedule of study assessments for corresponding visits in PA0012  
Table 5 -2 h Only subjects affected by enthesitis 
or dactylitis at Baseline from 
PA0010 or PA0011.  
i Adverse events not related to the 
device presentations will be 
reported in PA0012 and adverse 
device effects and device 
deficiencies will be reported in 
DV0004. A single safety database 
will be used for both studies.  h Only subject s affected by enthesitis 
or dactylitis at Baseline from 
PA0010 or PA0011.  
i Adverse events not related to the 
device presentations will be 
reported in PA0012 and adverse 
device effects and device 
deficiencies will be reported in 
DV0004. A single safety dat abase 
will be used for both studies.  Deleted original h footnote since 
there is no longer a restriction in 
PA0012 for LDI or LEI assessment 
to avoid potentially missing data. 
Analysis for LDI and LEI will still 
be performed on subjects having 
dactylitis or  enthesitis at Baseline 
of PA0010 or PA0011.  
Footnote for adverse events moves 
from i to h.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 47 of 49 Protocol section 
impacted  Key components of previous 
protocol text  Key components of revised protocol 
text Rationale  
Change 3: Update schematic diagram  
Section 5.3,  
Figure 5 -1 Visit 3, Week 8 (in PA0012) : 
• Pre-injection PK sample  
• Injection by study personnel  
OR self -injection after training  Visit 3, Week 8 (in PA0012) : 
• Pre-injection PK sample  
• Injection by study personnel  
OR self injection after training  IMP administration at Week 8 
should be performed by study site 
staff only.   
Change 4: Update description of IMP  
Section 7.2 Bimekizumab will be supplied at a 
concentration of 160mg/mL (55mM 
sodium acetate, 220mM glycine, 
0.04% polysorbate 80 at pH 5.0) for sc 
injection in the bimekizumab -SS-1mL 
or the bimekizumab AI 1mL device 
presentations.  Bimekizumab will be supplied at a 
concentration nominal  formulation of 
160mg/mL (in 55mM sodium acetate, 
220mM glycine, and 0.04% 
polysorbate 80 at pH 5.0 ) for sc 
injection in the bimekizumab -SS-1mL 
or the bimekizumab AI 1mL device 
presentations.  Updated to be consistent with other 
studies in bimekizumab clinical 
development program.  
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 48 of 49 19 DECLARATION AND SIGN ATURE OF INVESTIGATO R 
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and local 
laws and requirements.  
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.  
I have received and read  all study -related information provided to me.  
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially and will not be made available to third parties without prior authorization by UCB.  
All rights  of publication of the results reside with UCB, unless other agreements were made in a 
separate contract.  
Investigator:  
 
   
Printed name   Date/Signature  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
UCB   14 May 2020  
Clinical Study Protocol  Bimekizumab  DV0004  
   
Confidential  Page 49 of 49 20 SPONSOR DECLARATION  
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof. 